Scientific Advisory Board
PsiOxus Therapeutics have world leading Scientific Founders and Advisors.
Professor Stefan Anker
Professor Stefan Anker is a Scientific Founder of Myotec Therapeutics Ltd. He is Professor of Cardiology and Cachexia Research at the Charité, Campus Virchow-Klinikum in Berlin, Germany. Professor Anker trained in medicine at the Charité Medical School in Berlin, and earned his Ph.D. at Imperial College London, whilst studying cachexia in chronic heart failure. Since 2000, Professor Anker has organised the International Cachexia Congresses [www.cachexia.org] and has more recently organised two International Cachexia Consensus meetings in Washington DC on the clinical definition of cachexia and clinical trial endpoints respectively. He is the author of more than 280 original papers, reviews, guidelines and editorials. His published work addresses the pathophysiology, treatment and prevention of heart failure and cachexia. Stefan has been Chairman or Steering Committee member for many major morbidity/mortality trials is on the executive committee of the board of the European Heart Failure Association and serves on the editorial boards of several peer reviewed journals most recently becoming the founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle.
Professor Andrew Coats
Professor Andrew Coats is a scientific founder and founding Board member of Myotec Therapeutics Ltd. He trained in Medicine at the Universities of Oxford and Cambridge and holds higher doctorates from Oxford and Imperial College and an MBA from the London Business School. He was the first Viscount Royston Professor at the National Heart and Lung Institute, becoming director of Cardiology at the Royal Brompton Hospital and then Associate Medical Director of the Royal Brompton and Harefield NHS Trust. He was then Dean of Medicine at the University of Sydney, becoming Deputy Vice-Chancellor in 2006. He is Editor-in-Chief of the International Journal of Cardiology and has more than 1,000 publications including 450 full papers in peer-reviewed journals and over 18,000 career citations. Andrew has been Chairman or Steering Committee member for many major morbidity/mortality trials. He has received the Linacre Medal of the Royal College of Physicians and gave the Inaugural Michael L. Pollock Memorial Lecture of the American Heart Association. In 2010, Professor Coats was appointed the Norwich Research Park Professor-at-large, University of East Anglia. Professor Coat's current affiliations are held as Joint Academic Vice-President at the Monash University, Australia and Director of the Monash Warwick Alliance at the University of Warwick, UK.
Dr Kerry Fisher
Dr Kerry Fisher is a Scientific Founder of Hybrid Biosystems Ltd. As well as serving on the Board he has held roles as Chief Scientific Officer and CEO. He is a gene delivery specialist working with therapeutic viruses for the treatment of cancer and for vaccination against infectious disease. His areas of interest include pharmacology and medicinal virology, with a particular interest in the modification of viruses for clinical use. Kerry achieved a 1st class undergraduate degree from the University of Aberdeen and completed his PhD in 2001 at the University of Birmingham. Since graduating Kerry has published over 40 articles and won several awards for his work. As well as his role as Chief Scientific Officer at PsiOxus Therapeutics, Kerry also holds an academic position as Lecturer at the University of Oxford.
Professor Len Seymour
Professor Len Seymour is a scientific founder and former Board member of Hybrid Biosystems Ltd. He is Chair of Gene Medicine at the University of Oxford and Head of the department of Clinical Pharmacology. He was the founding President of the British Society for Gene Therapy and is currently Secretary General of the European Society for Gene & Stem Cell Therapy. Len is a world authority on gene based treatments with over 120 publications. He has raised over £20 million in research funding and holds positions on a number of advisory and editorial boards. His research activities are particularly directed towards new treatments for cancer at the interface of stem cell and genetic technologies, focusing on strategies for improving motility and engraftment of therapeutic cells within sites of tissue damage, including delivery of therapeutic viruses and gene constructs.
Dr Terry Hermiston
Dr Terry Hermiston is the Vice President of Biologics at Bayer Healthcare Pharmaceutical, Inc. and is the inventor of the ColoAd1 oncolytic vaccine, which PsiOxus Therapeutics will take into phase I/II clinical trials in 2012. Dr Hermiston brings invaluable expertise in the discovery and development of novel biologics in general and oncolytic vaccine in particular. Before joining Bayer (previously Berlex), Dr Hermiston was Associate Director of Oncolytic Virus Research at Onyx Pharmaceuticals. He is broadly published in the field of viral therapeutics and is the author of nine granted patents within the field. Dr Hermiston also currently serves as the Site Head of the Bayer Innovation Center in San Francisco's Mission Bay. Dr Hermiston received his PhD from the University of Iowa.